A Single Institution Experience With Induction Chemotherapy (ICT) Followed by Chemoradiation (CRT) Versus CRT for Definitive Treatment of Locally Advanced Squamous Cell Carcinoma of the Head and Neck (LA-SCCHN)

Abstract

the 13 patients who developed DM, the LN levels involved were: Level I (3 pts), Level II (12 pts), Level III (8 pts), Level IV (7 pts), Level V (6 pts) and RP group (2 pts). Hence, the risk of DM stratified based on each LN level was calculated as follows: Level I (33%), Level II (20%), Level III (20%), Level IV (39%), Level V (46%) and RP group (33%). The 3 patients with DM who had Level I LN involved had extra-oral cavity primaries with multi-level involvement (Supraglottic Larynx “level I-V”, Base of Tongue ”Levels I,III,IV” and Tonsil “Level I-II”). The most common site for DM was lung (8 pts), followed by bones (5), liver (2) and brain (1). Conclusions: Patients with HNSCC who have involved Lymph Node levels IV, V or RP group are associated with 33-46% risk of DM on this cohort and should be considered to be further assessed for the role of adjuvant systemic therapy. Author Disclosure: H. AlHussain: None. I. Busca: None. L. Eapen: None. S. El-Sayed: None.